Med. praxi. 2022;19(3):181-186 | DOI: 10.36290/med.2022.028

Non-interventional therapy in peripheral artery disease

MUDr. Ivo Hofírek
AngioClinic Brno, s. r. o.

The article deals with preventive and non-interventional treatments in peripheral artery disease of the lower limbs: physical training, influencing risk factors such as smoking and appropriate therapy for diabetes, hyperlipidemia, and hypertension, antiplatelet (or anticoagulant) therapy, the use of vasoactive drugs, and views on therapeutic angiogenesis (cellular and gene therapy).

Keywords: peripheral arterial disease, physical training, anti-aggregation, lipid-lowering therapy.

Published: June 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hofírek I. Non-interventional therapy in peripheral artery disease. Med. praxi. 2022;19(3):181-186. doi: 10.36290/med.2022.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Conte SM, Vale PR. Peripheral arterial disease. Heart Lung Circ. 2018;27:427-32. Go to original source... Go to PubMed...
    2. Criqui MH, Aboyans V. Epidemiology of peripheral arterial disease. Circ Res. 2015;116:1509-26. Go to original source... Go to PubMed...
    3. Fowkes FGR, Aboyans V, Fowkes FJI, et al. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2016;14:156-70. Go to original source... Go to PubMed...
    4. McDermott MM, Ferrucci L, Guralnik J, et al. Pathophysiological changes in calf muscle predict mobility loss at 2-year follow­‑up in men and women with peripheral arterial disease. Circulation. 2009;120:1048-1055. doi: 10.1161/CIRCULATIONAHA.108.842328. Go to original source... Go to PubMed...
    5. Szuba A, Oka RK, Harada R, et al. Limb hemodynamics are not predictive of functional capacity in patients with PAD. Vasc Med. 2006;11:155-163. doi: 10.1177/1358863x06074828. Go to original source... Go to PubMed...
    6. Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat Rev Cardiol. 2022 Jan 7. doi: 10.1038/s41569-021-00663-9. Epub ahead of print. PMID: 34997200. Go to original source... Go to PubMed...
    7. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146. doi: 10.1002/14651858.CD000146.pub4. Update in: Cochrane Database Syst Rev. 2018 May 31;5:CD000146. PMID: 23152200. Go to original source... Go to PubMed...
    8. Parvar SL, Fitridge R, Dawson J, et al. Medical and lifestyle management of peripheral arterial disease, Journal of Vascular Surgery. 2019;68(5):1595-1606. https://doi.org/10.1016/j.jvs.2018. 07. 027. Go to original source...
    9. Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circulation Research. 2021;128:1868-1884. doi.org/10.1161/CIRCRESAHA.121.318258. Go to original source... Go to PubMed...
    10. Frank U, Nikol S, Belch J, et al. ESVM Guideline on peripheral arterial disease. Vasa. 2019;48(Suppl 102):1-79. doi: 10.1024/0301-1526/a000834. Go to original source... Go to PubMed...
    11. Rivera­‑Caravaca JM, Camelo­‑Castillo A, Ramírez­‑Macías I, et al. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. Int J Mol Sci. 2021 Jul 1;22(13):7113. doi: 10.3390/ijms22137113. PMID: 34281167; PMCID: PMC8267774. Go to original source... Go to PubMed...
    12. Gerhard­‑Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686-e725. DOI: 10.1161/CIR.0000000000000470. Go to original source... Go to PubMed...
    13. Aboyans V, Bauersachs R, Mazzolai L, et al., Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy, European Heart Journal. 2021;42(39):4013-4024. https://doi.org/10.1093/eurheartj/ehab390. Go to original source... Go to PubMed...
    14. Peters F, Kuchenbecker J, Kreutzburg T, et al. Long­‑term effectiveness and safety of initiating statin therapy after index revascularization in patients with peripheral arterial occlusive disease. J Am Heart Assoc. 2020;9:e018338. doi: 10.1161/JAHA.120.018338. Go to original source... Go to PubMed...
    15. Sofat S, Chen X, Chowdhury MM, et al. Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta­‑analysis. Eur J Vasc Endovasc Surg. 2021;62(3),450-461. doi: https://doi.org/10.1016/j.ejvs.2021. 05. 025 Go to original source...
    16. Treat­‑Jacobson D, McDermott MM, Bronas UG, et al. American Heart Association Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Council on Cardiovascular and Stroke Nursing. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10-e33. doi: 10.1161/CIR.0000000000000623. PMID: 30586765. Go to original source... Go to PubMed...
    17. Lane R, Harwood A, Watson L, et al. Exercise for intermittent claudication.Cochrane Database Syst Rev. 2017;12:CD000990. doi: 10.1002/14651858.CD000990.pub4. Go to original source... Go to PubMed...
    18. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol. 2015;65:999-1009. doi: 10.1016/j.jacc.2014. 12. 043. Go to original source...
    19. Harwood AE, Pymer S, Ibeggazene S, et al. Provision of exercise services in patients with peripheral artery disease in the United Kingdom. Vascular. August 2021. doi:10.1177/17085381211035259. Go to original source... Go to PubMed...
    20. Goldman MP, Clark CJ, Craven TE, et al. Effect of intensive glycemic control on risk of lower extremity amputation. J Am Coll Surg. 2018;227:596-604. doi:10.1016/j.jamcollsurg.2018. 09. 021. Go to original source... Go to PubMed...
    21. Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE­‑TIMI 58. Circulation. 2020;142:734-747. doi: 10.1161/CIRCULATIONAHA.119.044775. Go to original source... Go to PubMed...
    22. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre­‑diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020 Dec 1;41(45):4317. PMID: 31497854. Go to original source... Go to PubMed...
    23. Bevan GH and White Solaru KT. Evidence­‑Based Medical Management of Peripheral Artery Disease. Thrombosis, and Vascular Biology. 2020;40:541-553. https://doi.org/10.1161/ATVBAHA.119.312142Arteriosclerosis, Go to original source...
    24. Squires H, Simpson E, Meng Y, et al. Cilostazol, nadtidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technology Assessment. 2010. Go to original source...
    25. Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014:CD003748. Go to original source...
    26. Uccioli L, Meloni M, Izzo V, et al. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag. 2018 Apr 26;14:63-74. doi: 10.2147/VHRM.S125065. PMID: 29731636; PMCID: PMC5927064. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.